Mesa Laboratories (MLAB) CFO John Sakys Buys 8,416 Shares

CFO John Sakys Expands Stake in MLAB

Mesa Laboratories, Inc. (NasdaqGS: MLAB) recently saw significant insider activity when Chief Financial Officer John Sakys picked up 8,416 shares on June 15, 2026. This trade stands out as a sizable addition by a top financial officer, catching the eye of market watchers tracking executive confidence in the scientific and technical instruments firm.

Busy Month of Insider Trading at Mesa Laboratories

The CFO's purchase arrived during a very active month for executive trades at the Lakewood-based company. On June 18, 2026, SVP of Operations Brian Archbold sold 2,480 shares, but also stepped up to buy 3,324 shares at a price of $95.10 for a total value of $316,112.40. On that same day, Chief Accounting Officer Lyndsey Crennen bought 263 shares at $95.10 worth $25,011.30, while separately selling 233 shares. The activity continued into June 22, 2026, when Archbold sold 2,516 shares at $89.50 valued at $225,182.00, and Crennen sold 442 shares at $89.50 worth $39,559.00. None of these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan.

Where MLAB Stock Trades Today

Shares of Mesa Laboratories change hands around $104.08, sitting comfortably above their 52-week low of $63.48 and below their peak of $132.70. The equity trades near its 50-day moving average of $112.70 and stays above its 200-day moving average of $97.02. With a market capitalization of roughly $737.9 million, the firm maintains a forward P/E ratio of 12.84.

Wells Fargo Updates Analyst Outlook

Wall Street firms continue to keep tabs on the company's valuation and growth path. On August 14, 2026, Wells Fargo maintained its equal-weight rating on the stock while raising its price target to $110.00 from $94.00. Across the analyst community, MLAB holds a mean price target of $117.50 based on two analyst opinions, with targets stretching from a low of $110.00 up to $125.00.

What Mesa Laboratories Actually Does

Mesa Laboratories develops and sells life sciences tools and quality control systems for medical, pharmaceutical, and industrial clients. Its operations span sterilization indicators, automated protein analysis systems like Gyrolab, peptide synthesis tools, and genomic testing instruments such as MassARRAY. These products help laboratories ensure safety, measure calibration parameters, and run genetic testing assays.

Upcoming Earnings and Key Milestones

Investors will keep a close eye on upcoming regulatory filings and prepare for the company's next scheduled earnings release on November 5, 2026. Further updates from leadership will help clarify how these executive trades align with the firm's financial trajectory.